Valley Fever Market Report 2026

The valley fever market size has grown strongly in recent years. It will grow from $1.05 billion in 2025 to $1.1 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to improved clinical recognition of fungal infections, availability of established antifungal medications, rising reported cases in endemic areas, increased diagnostic testing, expansion of infectious disease treatment centers.

The valley fever market size is expected to see strong growth in the next few years. It will grow to $1.35 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to growing focus on rapid diagnostic tools, increasing investment in novel antifungal therapies, expansion of disease surveillance programs, rising awareness of climate-related disease spread, increasing demand for effective long-term treatment options. Major trends in the forecast period include increasing focus on early diagnosis and treatment, growing use of antifungal drug therapies, rising awareness in endemic regions, expansion of combination treatment approaches, increasing research into fungal disease management.

The increasing exposure to fungus spores is expected to drive the growth of the valley fever market in the coming years. Fungus spores are microscopic reproductive units produced by fungi that can spread through air, water, or surfaces, allowing the fungus to grow and reproduce in new environments. Exposure to these spores is rising due to deforestation and changing weather patterns, which disturb soil and release spores, increasing the risk of infections such as valley fever - particularly in arid regions where the Coccidioides fungus thrives. Treatments for valley fever help patients by alleviating symptoms, preventing complications, and controlling fungal growth, ultimately improving recovery and quality of life. For example, in September 2024, the International Society for Infectious Diseases, a US-based nonprofit organization, reported that invasive fungal infections affect about 6.5 million people annually, resulting in nearly 3.8 million fatalities, of which approximately 2.5 million are directly attributable to these infections. Therefore, rising exposure to fungus spores is driving growth in the valley fever market.

The expansion of healthcare facilities is expected to support the growth of the valley fever market going forward. Healthcare facilities include the physical infrastructure, systems, and resources needed to deliver effective medical services. Growth in healthcare facilities is driven by advancements in medical technology, as innovations like telemedicine, robotic surgery, and AI-driven diagnostics require upgraded infrastructure, specialized equipment, and improved healthcare delivery systems to enhance patient outcomes and efficiency. Healthcare facilities aid in managing valley fever by enabling early diagnosis, providing antifungal treatments, offering patient education, and ensuring ongoing care to control symptoms and prevent complications. For example, in July 2025, Eurostat, the Luxembourg-based statistical office of the European Union, reported that the EU had 511 hospital beds per 100,000 people in 2023, with Bulgaria recording the highest ratio in the region at 864 beds per 100,000 people. Therefore, the expansion of healthcare infrastructure is driving the growth of the valley fever market.

Leading companies in the valley fever market are focusing on the development of innovative vaccines to address the growing threat of fungal infections. Valley fever vaccines aim to protect populations using advanced scientific and manufacturing techniques, improving public health and safety. For example, in August 2024, Anivive Lifesciences Inc., a US-based pet pharmaceutical company, received a contract worth up to $33 million from the National Institute of Allergy and Infectious Diseases (NIAID), a US government agency, to develop a human vaccine for valley fever. The funding will support additional manufacturing, formulation, extensive safety testing, and a Phase 1 clinical trial, with the goal of delivering the first vaccine to prevent this serious systemic fungal infection.

Major companies operating in the valley fever market are Merck & Co Inc, Fresenius Kabi, Dr Reddys Laboratories, Mankind Pharma, Atom Pharma, Cerata Pharmaceuticals, Pfizer Inc, Novartis AG, Sanofi S A, GlaxoSmithKline plc, Bayer AG, Astellas Pharma Inc, Abbott Laboratories Inc, SCYNEXIS Inc, Leadiant Biosciences Inc, Amplyx Pharmaceuticals Inc, Johnson & Johnson, Bristol Myers Squibb, Gilead Sciences Inc, Viatris Inc, Teva Pharmaceuticals USA Inc.

North America was the largest region in the valley fever market in 2025. The regions covered in the valley fever market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the valley fever market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the valley fever market by increasing costs of imported antifungal drugs, diagnostic kits, laboratory reagents, and pharmaceutical manufacturing inputs. North America is most affected due to the regional concentration of valley fever cases and reliance on imported drug components, while other regions face limited availability and higher treatment costs. These tariffs are increasing healthcare expenditure and affecting patient access to therapies. However, they are also encouraging domestic production of antifungal medications, localized diagnostic manufacturing, and improved supply chain resilience for infectious disease treatments.

The valley fever market research report is one of a series of new reports that provides valley fever market statistics, including valley fever industry global market size, regional shares, competitors with a valley fever market share, detailed valley fever market segments, market trends and opportunities, and any further data you may need to thrive in the valley fever industry. This valley fever market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Valley fever, also known as coccidioidomycosis, is a fungal infection that primarily affects the lungs and can cause symptoms such as cough, fever, fatigue, and chest pain, with some cases leading to severe complications. It is caused by inhaling airborne spores of the Coccidioides fungi, which are commonly found in dry, dusty soil and can become airborne when the soil is disturbed.

The main treatment options for valley fever include fluconazole, itraconazole, voriconazole, posaconazole, and others. Fluconazole is an antifungal medication that treats fungal infections by inhibiting fungal growth. The infection can affect various sites, including the skin, lungs, liver, bones, heart, brain, and the membranes surrounding the brain and spinal cord, among others. These treatments are used for a range of end users, including humans, cattle, sheep and goats, camels, and others.

The valley fever market consists of sales of antifungal medications and steroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.